Gilead Exercises Option on Kymera’s CDK2 Degrader, Triggers $45M Milestone
Event summary
- Gilead Sciences exercised its option to exclusively license KT-200, Kymera’s oral CDK2 molecular glue degrader, triggering a $45 million milestone payment.
- KT-200 is the first molecular glue degrader discovered by Kymera to enter clinical development, targeting CCNE1-amplified cancers.
- Gilead plans to advance KT-200 into IND-enabling studies, with an IND filing expected in 2027.
- Kymera is eligible for up to $750 million in total payments under the collaboration, including tiered royalties on future sales.
The big picture
This deal underscores the growing interest in molecular glue degraders as a next-generation therapeutic approach, particularly for challenging cancer targets like CDK2. Kymera’s ability to attract high-value partnerships reflects the strategic shift toward precision oncology, where selective degradation of disease-causing proteins offers advantages over traditional inhibitors. The $750 million potential upside highlights the scale of investment in this emerging field.
What we're watching
- Clinical Progress
- How quickly KT-200 advances through IND-enabling studies and into clinical trials will determine its commercial viability.
- Revenue Potential
- Whether Gilead can successfully commercialize KT-200 and generate meaningful royalties for Kymera.
- Pipeline Expansion
- The pace at which Kymera can leverage this collaboration to secure additional partnerships for its targeted protein degradation platform.
Related topics